Key Takeaways
- Regulated markets drove a 60% YoY surge, powered by an ANDA portfolio that nearly quadrupled to 46 filings over the last year through in-house development and acquisitions.
- Emerging markets turned the corner on profitability, hitting their highest-ever quarterly revenue, EBITDA and PAT while becoming cash-flow positive, with margins improving to the mid-teens.
- Apnar Pharma acquisition closed last week, adding a US FDA-approved facility, five approved ANDAs, and an expected $16–$18 million in revenue over the next 12–15 months.
- Management reaffirmed FY26 guidance of 50% top-line growth and 100% PAT growth, with nine-month results tracking slightly ahead of the annual target.
- What to watch next quarter: Whether Apnar integration delivers the promised cash-flow positivity this quarter, the pace of emerging-market margin expansion toward 18%, and any FY27 guidance specifics management has so far declined to provide.
Regulated Markets (US) Performance
- 60% YoY growth in Q3 and 71% in 9MFY26, driven by product portfolio expansion, prudent sales channel selection, and differentiated go-to-market strategies. The ANDA portfolio grew from 12 to 46 ANDAs over the last year.
- Sustainable EBITDA margin is 40%, with the prior quarter's 44% being a one-off due to product mix and other income. Management expects to sustain or improve by roughly 1% as more own products enter the mix.
- Own products vs CDMO/CMO mix is expected at roughly 60/40 for the full year and next year. CDMO/CMO margins run 4%–6% lower than own products, so the mix shift toward own products supports gradual margin improvement.
- Controlled substances contribute roughly 15%–20% of overall revenue, with two controlled substance product launches planned for FY27.
- Launch cadence is accelerating: all 28 approved yet-to-be-launched ANDAs will be launched within the next six to eight quarters, and at least 10 of the 22 ANDAs under development will launch in the same window.
Deval Shah: "I think last quarter also we said that this 44% was a one-off, I think due to some product mix and other mix of income. But sustainable margin, what we see, gross margin, EBITDA margin for the US business is around 40%."
Apnar Pharma Acquisition
- Deal closed last week (as of Jan 20, 2026) with a 75% stake acquired; the remaining 25% is expected to close by Q2 FY27. Apnar is a US FDA-approved facility, also approved by UK MHRA and Health Canada.
- Five approved ANDAs come with the acquisition, expected to generate at least $16–$18 million in revenue over the next 12–15 months. The facility is expected to be cash-flow positive this quarter with three products launching from it.
- Revenue contribution for FY27 is projected at roughly ₹120–₹150 crore.
- Capacity flexibility: Apnar provides extended capacity immediately, and some low-margin products that do not require US manufacturing may be shifted to Apnar in India, freeing US capacity for higher-margin business.
- Margin expansion from Apnar remains unquantified: management called it "very early to say" and noted margins will expand when the facility reaches optimal utilization.
Swapnil Shah: "It is very early to say what kind of margin expansion that will happen from Apnar as we speak. However, we see margins expanding in when we reach that optimal number of utilization of that facility."
Emerging Markets Turnaround
- Highest-ever quarterly revenue, EBITDA, and PAT in Q3, with the business becoming cash-flow positive. EBITDA margin improved significantly toward the mid-teens range.
- 56 new product approvals in the quarter drove the improvement, alongside better per-unit metrics (roughly ₹2 per unit), a shift toward mixed molecules, and a refined go-to-market strategy yielding better pricing and margins.
- Portfolio depth: 450 registered products as of December 2025, with more than 850 products under registration. The commercialization of newly approved products will continue to drive the growth trajectory.
- FY27 margin path: management expects emerging-market EBITDA margins to stabilize at 18%, then reach 20%–22%, with further improvement of a couple of basis points over another three to four quarters.
- Revenue next year is projected at ₹170–₹180 crore, with the export-based, dollar-denominated revenue mix continuing to expand over the next four to six quarters.
- PIC/S approval for the Chhatral manufacturing facility is in process, which will enable expansion into key mid-tier markets.
India Branded Generics & CDMO
- India branded generics delivered ₹10.5 crore in Q3 (over 6x YoY) and ₹31 crore for 9M (over 7x YoY), continuing strong momentum. The current year is expected to conclude between ₹40–₹50 crore, with next year's projection at ₹80+ crore.
- CDMO-CMO traction is steady and scaling, with 16 commercial products covering more than 55 strengths. The moat comes from being an end-to-end solution provider spanning development, commercial production, and regulatory support.
- Stock-in-trade increase from ₹11 crore to ₹37 crore reflects the start of CMO manufacturing for own products in India across three locations plus Apnar; this includes outsourced production from third parties, as internal production gets knocked off on consolidation.
- Revenue recognition is contractual across both own products and CDMO/CMO: the company manufactures only on confirmed purchase orders, manufacturing capacities are pre-sold, and finished goods inventory is a maximum of 15 days.
Financial Position & Cash Flows
- Operating cash flow for 9M FY26 reached roughly ₹51 crore, with EBITDA-to-operating-cash-flow conversion improving significantly over the last year despite robust business growth.
- Other expenses fell to ₹22 crore in Q3 due to consolidation and rationalization of certain expenditure.
- Consolidated EBITDA margin is expected to reach roughly 30% blended by the end of FY26, up from the current 29%.
- Capex for the next 2–3 years is expected at roughly ₹50–₹100 crore depending on requirement; earlier planned capex in the US may be adjusted since Apnar is now available. The Atlanta Oral Solid Facility capacity expansion from 100 crore to 200 crore tablets is likely to be completed next year.
- Promoter warrants were issued recently because IPO proceeds have specific earmarks (₹100 crore for the Atlanta facility) and cash on hand was only ₹25 crore as of December 31, further reduced by the Apnar acquisition. A small promoter share pledge was taken to consolidate some borrowings and is not likely to increase.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY26 top-line growth | 50% growth over FY25 | FY26 full year |
| FY26 PAT growth | 100% growth over FY25 | FY26 full year |
| FY26 consolidated EBITDA margin | Reach roughly 30% blended | By end of FY26 |
| Apnar revenue contribution | ₹120–₹150 crore | FY27 |
| India branded generics revenue | ₹80+ crore | FY27 |
| Emerging markets revenue | ₹170–₹180 crore | FY27 |
| Regulated markets own-product/CDMO mix | Roughly 60/40 | FY27 |
| ANDA launches from approved pipeline | All 28 approved yet-to-be-launched ANDAs | Next 6–8 quarters |
| ANDA launches from development pipeline | At least 10 of 22 ANDAs under development | Next 6–8 quarters |
| Controlled substance launches | Two launches | FY27 |
| Emerging markets EBITDA margin | Stabilize at 18%, then 20%–22% | FY27, then further improvement over 3–4 quarters |
| Capex | Roughly ₹50–₹100 crore | Next 2–3 years |
| Minimum growth target | 25% plus (can be better) | FY27 |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Consolidated revenue | ₹175 cr, +64% YoY |
| Regulated markets revenue | ₹113 cr, +60.5% YoY |
| Emerging markets revenue | ₹38 cr, +47.5% YoY |
| India branded generics revenue | ₹10.5 cr, over 6x YoY |
| Consolidated EBITDA | ₹54 cr, +86% YoY |
| Consolidated EBITDA margin | 30.9%, +360 bps YoY and +30 bps QoQ |
| PAT after minority interest | ~₹32 cr, ~85% YoY growth |
| 9M FY26 consolidated revenue | ₹474 cr, +65% YoY |
| 9M FY26 EBITDA margin | 29%, +340 bps YoY |
| 9M FY26 PAT margin | 17.7%, +350 bps YoY |
| 9M FY26 operating cash flow | ~₹51 cr, significant improvement over last year |
| Approved ANDAs | 46, covering 137+ product trends, nearly quadrupled from 12 in Dec 2024 |
| ANDAs launched | 18 launched; 28 approved with 100+ strengths available for launch |
| ANDAs under development | 22 molecules with 50+ strengths |
| CDMO-CMO commercial products | 16 products, 55+ strengths |
| Emerging market registered products | 450 as of Dec 2025; 56 new approvals in Q3; 850+ under registration |
| Emerging market per unit metric | ~₹2 per unit |
| Regulated market revenue mix | ~55% own products, ~45% CDMO/CMO; full year expected ~60%/40% |
| Controlled substance revenue contribution | ~15%–20% of overall revenue |
| Apnar Pharma acquisition stake | 75% completed; balance 25% expected by Q2 FY27 |
| Apnar expected revenue contribution | $16–$18 million in next 12–15 months from 5 approved ANDAs |
| India branded generics FY26 guidance | ₹40–₹50 cr |
| Emerging markets FY27 revenue guidance | ₹170–₹180 cr |
| US-regulated business sustainable EBITDA margin | ~40% |
| Emerging markets EBITDA margin target | upwards to close to 20% at peak; FY27 expectation 18%–22% |
| Net working capital cycle | ~90–94 days |
| Capex expectation next 2–3 years | ₹50–₹100 cr |